A clinical trial has shown that a new drug combination taken over 12 weeks, can effectively treat hepatitis C genotypes 1, 2, 4, 5 and 6.
The study, published in the New England Journal of Medicine, reported that a combination of sofosbuvir and velpatasvir, achieved successful results in people who were previously treated, as well as those never treated before for their hepatitis C.
CBC News reported that the drug combination was investigated in a randomized, placebo-controlled trial at 81 sites in eight different countries.
After 12 weeks of treatment, 99 per cent of the 624 patients given sofosbuvir-velpatasvir were virus-free three months after completing treatment. None of the 116 patients receiving a placebo had the same result.
Image by Fauxto_Digit via Flickr on Creative Commons Licence
